Amanda Brown
Family · Leesville, LANPI 1275913360
Payments from drug & device makers
Across 141 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$430
- Insulet Corporation$294
- Lilly USA, LLC$250
- Amgen$241
- Corcept Therapeutics$239
- Bayer$192
- plus $851 from 16 others
What the payments were for
- Food & beverage$2,497100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 31 | $430 |
| Insulet Corporation | 13 | $294 |
| Lilly USA, LLC | 14 | $250 |
| Amgen(2 entities) | 16 | $241 |
| Corcept Therapeutics | 10 | $239 |
| Bayer | 11 | $192 |
| AbbVie | 7 | $144 |
| Novo Nordisk | 8 | $132 |
| Forte Bio-pharma LLC | 7 | $99 |
| Medtronic | 3 | $97 |
| Tandem Diabetes Care, Inc. | 4 | $66 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Exact Sciences | 3 | $48 |
| Amryt Pharma Holdings Ltd | 2 | $46 |
| Merck | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Novartis | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Abbott | 1 | $12 |
How this compares
$2,497 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 359 | $554,705 |
| JardianceEmpagliflozin | 318 | $346,070 |
| MounjaroTirzepatide | 93 | $105,512 |
| JanuviaSitagliptin Phosphate | 68 | $64,440 |
| Tresiba Flextouch U-200Insulin Degludec | 46 | $61,160 |
| EliquisApixaban | 76 | $59,602 |
| FarxigaDapagliflozin Propanediol | 52 | $55,595 |
| EntrestoSacubitril/Valsartan | 32 | $55,303 |
| TradjentaLinagliptin | 68 | $54,595 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 34 | $42,126 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $39,715 |
| TrulicityDulaglutide | 18 | $36,429 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $22,731 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $22,357 |
| LinzessLinaclotide | 33 | $21,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $132 | $561,043370 claims |
| Lilly USA, LLCMounjaro, Trulicity | $250 | $141,941111 claims |
| MerckJanuvia, Janumet | $30 | $82,37692 claims |
| NovartisEntresto | $17 | $55,30332 claims |
| AbbVieLinzess | $144 | $21,63733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.
Other family in Leesville
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.